(3R,5S,8S,15E)-8-t-butyl-N-((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-7,10-dioxo-2,11-dioxa-6,9,23-triazatetracyclo[15.6.2.1-3,6-.0-20,24-]hexacosa-1(23),15,17,19,21,24-hexaene-5-carboxamide | 924269-21-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3R,5S,8S,15E)-8-t-butyl-N-((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-7,10-dioxo-2,11-dioxa-6,9,23-triazatetracyclo[15.6.2.1-3,6-.0-20,24-]hexacosa-1(23),15,17,19,21,24-hexaene-5-carboxamide
• 英文别名: (2R,4S,7S,14E)-7-tert-Butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-6,9-dioxo-3,4,6,7,8,9,12,13-octahydro-2H,11H-16,18-(ethanediylidene)-2,5-methanopyrido[2,3-k][1,10,3,6]dioxadiazacyclononadecine-4-carboxamide；(3R,5S,8S,15E)-8-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7,10-dioxo-2,11-dioxa-6,9,23-triazatetracyclo[15.6.2.13,6.020,24]hexacosa-1(23),15,17(25),18,20(24),21-hexaene-5-carboxamide
• CAS: 924269-21-6
• 化学式: C₃₅H₄₃N₅O₈S
• 分子量: 693.821
• InChiKey: WSIXKAHFCWLWHX-WYSYMYBTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  49
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  182
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  1-氨基-N-(环丙基磺酰基)-2-乙烯基-环丙烷羧胺盐酸盐 、 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以13.0 g的产率得到(3R,5S,8S,15E)-8-t-butyl-N-((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)-7,10-dioxo-2,11-dioxa-6,9,23-triazatetracyclo[15.6.2.1-3,6-.0-20,24-]hexacosa-1(23),15,17,19,21,24-hexaene-5-carboxamide
  参考文献：
  名称：

  Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease

  摘要：

  Molecular modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors. Optimization of initial compounds provided 25a. The in vitro activity and selectivity as well as the rat pharmacokinetic profile of 25a compare favorably with the data for other NS3/4A protease inhibitors currently in clinical development for the treatment of HCV.

  DOI：

  10.1021/ja711120r